Biogen Pays $124 Million to Develop Gene-Based Therapies
On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing its products, and co
Login
X
- New Ventures
- Market Analysis
- Emerging Markets
- Technology
- Professional Services
- Media & Entertainment
- Manufacturing & Retail
- Logistics & Supply Chain
- Healthcare & Pharmaceutical
- Financial Services
- Energy
- Autos
- Aerospace & Defense
- Work-Life Balance
- Strategic Thinking
- Productivity
- Decision Making
- Communication
- Sustainability
- Success Story
- Power Players
- Philanthropy
- People
- Innovation
- CEO Magazine
